{"ticker": {"uuid": "fbb34216-4127-4ac5-80fe-93adab30edc9", "symbol": "MSLE", "name": "Satellos Bioscience Inc. Common Stock", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Price to book forward of Satellos Bioscience Inc \u2013 SWB:0IT", "summary": "This article provides financial information for Satellos Bioscience Inc (SWB:0IT), specifically its price to book forward value. The data is available on TradingView, which aggregates market data from ICE Data Services and reference data from FactSet. The company is listed on the", "url": "https://www.tradingview.com/symbols/SWB-0IT/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-13T05:40:08", "published_display": "13 Jul 2026 05:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech With Muscle Disease Drug Uncovers Results in Trial Data", "summary": "Satellos Bioscience Inc. released promising six-month interim data from its TRAILHEAD study for SAT-3247, an investigational drug for Duchenne muscular dystrophy (DMD). The drug showed reduced muscle fat, increased effort, and stable strength in adult participants, leading analys", "url": "https://www.streetwisereports.com/article/2026/07/09/biotech-with-muscle-disease-drug-uncovers-results-in-trial-data.html", "source_name": "Streetwise Reports", "published_at": "2026-07-11T08:12:14", "published_display": "11 Jul 2026 08:12", "sentiment": "positive", "sentiment_pct": 71, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Satellos Bioscience DMD Drug Shows Early Promise in 6-Month Study Update", "summary": "Satellos Bioscience announced promising interim six-month data for its Duchenne muscular dystrophy (DMD) drug, SAT-3247, from the ongoing TRAILHEAD study involving adult participants. The results indicate encouraging safety and efficacy signals, including improvements in muscle f", "url": "https://www.tradingview.com/news/marketbeat:23ce83e80094b:0-satellos-bioscience-dmd-drug-shows-early-promise-in-6-month-study-update/", "source_name": "TradingView", "published_at": "2026-07-11T07:10:39", "published_display": "11 Jul 2026 07:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Satellos Bioscience Inc. - Common Stock (MSLE) Stock Price, News, Quote & History", "summary": "Satellos Bioscience Inc. (MSLE) stock is trading at $9.79, up 3.71%. Recent news highlights promising early data for its DMD drug SAT-3247 from the TRAILHEAD study and upcoming presentations at medical and investor conferences. The company also recently completed a US$57.2 millio", "url": "https://www.financialcontent.com/quote/NQ:MSLE", "source_name": "FinancialContent", "published_at": "2026-07-11T01:40:32", "published_display": "11 Jul 2026 01:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Satellos Bioscience Delivers Promising DMD Data With Fast Track Win", "summary": "Satellos Bioscience reported promising six-month data from its TRAILHEAD study for SAT-3247 in adult Duchenne muscular dystrophy (DMD) patients, showing muscle fat reduction and improved function. The company also secured FDA Fast Track designation for SAT-3247, which is an oral ", "url": "https://www.streetwisereports.com/article/2026/07/09/satellos-bioscience-delivers-promising-dmd-data-with-fast-track-win.html", "source_name": "Streetwise Reports", "published_at": "2026-07-10T16:40:32", "published_display": "10 Jul 2026 16:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Satellos Bioscience stock price target raised to $18 by H.C. Wainwright on trial data", "summary": "H.C. Wainwright has raised its price target for Satellos Bioscience Inc. (NASDAQ:MSLE) to $18 from $11, while maintaining a Buy rating, following positive interim trial results for its Duchenne muscular dystrophy drug, SAT-3247. The stock saw a 24% increase last week and a 59% ye", "url": "https://www.investing.com/news/analyst-ratings/satellos-bioscience-stock-price-target-raised-to-18-by-hc-wainwright-on-trial-data-93CH-4783828", "source_name": "Investing.com", "published_at": "2026-07-10T07:10:39", "published_display": "10 Jul 2026 07:10", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HC Wainwright Forecasts Strong Price Appreciation for Satellos Bioscience (NASDAQ:MSLE) Stock", "summary": "HC Wainwright has increased its price target for Satellos Bioscience (NASDAQ:MSLE) to $18 from $11, maintaining a \"buy\" rating and suggesting a 100% upside. Despite a recent earnings per share miss, the consensus among analysts is a \"Moderate Buy\" with an average target price of ", "url": "https://www.marketbeat.com/instant-alerts/hc-wainwright-forecasts-strong-price-appreciation-for-satellos-bioscience-nasdaqmsle-stock-2026-07-09/", "source_name": "MarketBeat", "published_at": "2026-07-09T12:40:57", "published_display": "09 Jul 2026 12:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Satellos\u2019 SAT-3247 Shows Muscle Fat Reduction in DMD Adults at Six Months", "summary": "Satellos Bioscience's drug candidate, SAT-3247, has shown promising interim results in its TRAILHEAD study for adult Duchenne muscular dystrophy (DMD) patients. All four participants, aged 21 to 28, experienced a decline in biceps brachii fat fraction, increased upper limb effort", "url": "https://www.clinicaltrialvanguard.com/news/satellos-sat-3247-shows-muscle-fat-reduction-in-dmd-adults-at-six-months/", "source_name": "The Clinical Trial Vanguard", "published_at": "2026-07-09T06:40:57", "published_display": "09 Jul 2026 06:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Satellos Reports Six-Month Interim TRAILHEAD Data Showing Reduced Muscle Fat Fraction, Increased Effort, Stable Strength, Lower CK and Favorable Safety Profile in DMD Adults Treated with SAT-3247", "summary": "Satellos Bioscience announced positive six-month interim data from its TRAILHEAD study for SAT-3247 in adults with Duchenne muscular dystrophy (DMD). The study showed reduced muscle fat fraction, increased upper limb effort, stable strength, lower creatine kinase levels, and a fa", "url": "https://ca.finance.yahoo.com/news/satellos-reports-six-month-interim-103000261.html", "source_name": "Yahoo! Finance Canada", "published_at": "2026-07-09T06:11:34", "published_display": "09 Jul 2026 06:11", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Satellos Bioscience Duchenne Drug Candidate's Interim Data Boosts Confidence", "summary": "Satellos Bioscience released positive six-month interim data from its TRAILHEAD study of SAT-3247 for Duchenne muscular dystrophy (DMD). The drug candidate showed improvements in muscle composition and upper limb activity, maintained stable strength, and continued to demonstrate ", "url": "https://finance.yahoo.com/healthcare/articles/satellos-bioscience-duchenne-drug-candidates-133420130.html", "source_name": "Market source", "published_at": "2026-07-08T20:12:41", "published_display": "08 Jul 2026 20:12", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phase II DMD Trailhead data hike Satellos\u2019 stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxOT2hrZDM5cUtzWUwtWE5aOHA4WVhFdzFsSEZmOWtVeGZIY0FJNjF0ZVFpOHFtT05pMUtrd0x6UlNLeG1yREdrYWNhLVRZYVkyTzQ2UVNHbUp1NUwxQUpMcXdjRG9BOGo2dWFUeGhkLU92Y0tTR0x6SjNFZWk4TGpsU01lUXF1VEhCbFZxVW1wdlhSQQ?oc=5", "source_name": "BioWorld News", "published_at": "2026-07-08T16:00:00+00:00", "published_display": "08 Jul 2026 16:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Satellos Bioscience's Share Rise After SAT-3247 Shows Positive Results for Duchenne MD", "summary": "Satellos Bioscience experienced a surge in its share price following positive preclinical results for its investigational drug, SAT-3247, in treating Duchenne muscular dystrophy (DMD). The study demonstrated that SAT-3247 effectively promoted muscle regeneration and increased mus", "url": "https://www.moomoo.com/news/post/72659943/satellos-bioscience-s-share-rise-after-sat-3247-shows-positive?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-08T15:40:20", "published_display": "08 Jul 2026 15:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Satellos reports positive TRAILHEAD data for DMD drug", "summary": "Satellos Bioscience announced positive six-month interim data from its TRAILHEAD study for Duchenne muscular dystrophy drug SAT-3247. Adult patients showed a mean muscle fat fraction reduction and improvements in upper limb maximum effort and creatine kinase levels. The drug main", "url": "https://grafa.com/en/news/united-states/satellos-bioscience-trailhead-interim-dmd-data", "source_name": "grafa.com", "published_at": "2026-07-08T14:40:20", "published_display": "08 Jul 2026 14:40", "sentiment": "positive", "sentiment_pct": 91, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Satellos Says Interim Phase 2 Data Shows SAT-3247 Improves Muscle Measures in Adult DMD Patients", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/satellos-says-interim-phase-2-122945620.html", "source_name": "MT Newswires", "published_at": "2026-07-08T12:29:45+00:00", "published_display": "08 Jul 2026 12:29", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Satellos\u2019 DMD drug shows better muscle metrics in 4 adults", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxOVFhDaHdPU3ZJUmlPMG1vbWlNZklXQnFnMy02LUwyclFULTdJbFJzcHlHRFdpa29RaldlSjZpd094WXoxaC02ZmJXdVpXS0RYN0Nva2Q1TnUxRFFPMjFoY2FVS1pfX1pxTlIzSU8xeEo2UWczczE5am5Bc0xGeEVCTlFPcE05eDBIc1h4Qml1RlZZaUJLSHZqUERNV19aU0pkd0dsQXlrR0kyZm5wZTRCdGxfNHVaOFk0Q25tbw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-08T10:30:00+00:00", "published_display": "08 Jul 2026 10:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[6-K] Satellos Bioscience Inc. Current Report (Foreign Issuer) | MSLE SEC Filing - Form 6-K", "summary": "Satellos Bioscience Inc. reported positive six-month interim data from its TRAILHEAD Phase 2 study of SAT-3247 in adults with Duchenne muscular dystrophy (DMD), showing reduced muscle fat fraction, increased total effort, stable strength, and a favorable safety profile. The compa", "url": "https://www.stocktitan.net/sec-filings/MSLE/6-k-satellos-bioscience-inc-current-report-foreign-issuer-12f4e1f06014.html", "source_name": "Stock Titan", "published_at": "2026-07-08T10:39:11", "published_display": "08 Jul 2026 10:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "If You Invested $1,000 in Satellos Bioscience Inc (MSCLF)", "summary": "This article analyzes the historical performance of Satellos Bioscience Inc. (MSCLF) stock, detailing how a $1,000 investment would have grown over 1, 5, and 10 years. It also provides an overview of the company, a clinical-stage biotechnology firm focused on restoring muscle rep", "url": "https://www.stocktitan.net/tools/stock-return-calculator/MSCLF", "source_name": "Stock Titan", "published_at": "2026-07-04T07:08:58", "published_display": "04 Jul 2026 07:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drug Developer Scores Major FDA Nod, Eyes Big Gains in Muscle Disease Market", "summary": "Satellos Bioscience Inc. (MSCL:TSX; MSLE:NASDAQ) has received FDA Fast Track designation for its Duchenne muscular dystrophy treatment, SAT-3247, aiming to accelerate its development. This designation, coupled with existing Orphan Drug and Rare Pediatric Disease designations, pos", "url": "https://www.streetwisereports.com/article/2026/07/01/drug-developer-scores-major-fda-nod-eyes-big-gains-in-muscle-disease-market.html", "source_name": "Streetwise Reports", "published_at": "2026-07-03T09:11:47", "published_display": "03 Jul 2026 09:11", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Satellos Bioscience Fast Track Win Fuels DMD Hopes", "summary": "Satellos Bioscience's SAT-3247, a treatment for Duchenne muscular dystrophy (DMD), has received FDA Fast Track designation, aiming to accelerate its regulatory review. The DMD market is projected for significant growth, reaching US$62.13 billion by 2030, presenting a substantial ", "url": "https://www.streetwisereports.com/article/2026/07/02/satellos-bioscience-fast-track-win-fuels-dmd-hopes.html", "source_name": "Streetwise Reports", "published_at": "2026-07-03T00:09:43", "published_display": "03 Jul 2026 00:09", "sentiment": "positive", "sentiment_pct": 82, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Satellos Receives FDA Fast Track Designation for SAT-3247 for the Treatment of Duchenne Muscular Dystrophy", "summary": "Satellos Bioscience Inc. announced that the FDA has granted Fast Track designation to SAT-3247 for Duchenne muscular dystrophy, adding to its Orphan Drug and Rare Pediatric Disease designations. This designation aims to expedite the development and review of SAT-3247, which is cu", "url": "https://www.globenewswire.com/news-release/2026/06/29/3318825/0/en/satellos-receives-fda-fast-track-designation-for-sat-3247-for-the-treatment-of-duchenne-muscular-dystrophy.html", "source_name": "GlobeNewswire", "published_at": "2026-07-02T08:12:14", "published_display": "02 Jul 2026 08:12", "sentiment": "positive", "sentiment_pct": 94, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stocks in play: Satellos Bioscience Inc.", "summary": "Satellos Bioscience Inc. (T.MSCL) received Fast Track designation from the U.S. FDA for SAT-3247, its treatment for Duchenne. Following this announcement, the company's shares were trading up $1.09 at $11.29. This indicates positive market reaction to the regulatory development.", "url": "https://www.theglobeandmail.com/investing/markets/stocks/MSCL-T/pressreleases/3035535/stocks-in-play-satellos-bioscience-inc/", "source_name": "The Globe and Mail", "published_at": "2026-06-30T03:39:58", "published_display": "30 Jun 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Satellos Bioscience up near 10% as SAT-3247 Granted FDA Fast Track Designation", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/satellos-bioscience-near-10-sat-165226766.html", "source_name": "MT Newswires", "published_at": "2026-06-29T16:52:26+00:00", "published_display": "29 Jun 2026 16:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Satellos gets FDA Fast Track for SAT-3247", "summary": "Satellos Bioscience (NASDAQ:MSLE) has received FDA Fast Track designation for its drug SAT-3247, intended for the treatment of Duchenne muscular dystrophy. This designation aims to accelerate the development and regulatory review process for the drug, which already holds Orphan D", "url": "https://grafa.com/en/news/united-states/satellos-msle-sat3247-fda-fast-track-duchenne", "source_name": "grafa.com", "published_at": "2026-06-29T17:40:34", "published_display": "29 Jun 2026 17:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Satellos Bioscience Shares Climb After FDA Fast Track Designation", "summary": "Satellos Bioscience Inc. recently received Fast Track Designation from the FDA for their drug candidate SAT-3257, which aims to treat Duchenne Muscular Dystrophy. This designation is intended to expedite the development and review of drugs for serious conditions with unmet medica", "url": "https://www.moomoo.com/news/post/72197562/satellos-bioscience-shares-climb-after-fda-fast-track-designation?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-06-29T15:09:31", "published_display": "29 Jun 2026 15:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Satellos Bioscience Inc.", "summary": "Satellos Bioscience Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its drug candidate, SAT-3247, for the treatment of Duchenne muscular dystrophy. Following this news, the company's shares (T.MSCL) were trading up $1.09 at $1", "url": "https://www.baystreet.ca/stocksinplayarticles/47448/Stocks-in-Play-Satellos-Bioscience-Inc", "source_name": "Baystreet.ca", "published_at": "2026-06-29T14:40:34", "published_display": "29 Jun 2026 14:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Satellos Bioscience' SAT-3247 Secures US FDA Fast Track Status in Duchenne Muscular Dystrophy", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/satellos-bioscience-apos-sat-3247-120323176.html", "source_name": "MT Newswires", "published_at": "2026-06-29T12:03:23+00:00", "published_display": "29 Jun 2026 12:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA Fast Track boosts Satellos (NASDAQ: MSLE) SAT-3247 Duchenne program", "summary": "Satellos Bioscience Inc. announced its oral small-molecule drug candidate, SAT-3247, has received FDA Fast Track designation for Duchenne muscular dystrophy. This designation, along with existing Orphan Drug and Rare Pediatric Disease designations, is expected to expedite the dev", "url": "https://www.stocktitan.net/sec-filings/MSLE/6-k-satellos-bioscience-inc-current-report-foreign-issuer-f6bda54afa90.html", "source_name": "Stock Titan", "published_at": "2026-06-29T10:40:39", "published_display": "29 Jun 2026 10:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Satellos wins FDA Fast Track for Duchenne drug SAT-3247", "summary": "Satellos Bioscience Inc. announced that the FDA has granted Fast Track designation to its drug candidate SAT-3247 for the treatment of Duchenne muscular dystrophy. This designation, along with existing Orphan Drug and Rare Pediatric Disease designations, aims to expedite the deve", "url": "https://www.stocktitan.net/news/MSLE/satellos-receives-fda-fast-track-designation-for-sat-3247-for-the-bjk0qs9tlpum.html", "source_name": "Stock Titan", "published_at": "2026-06-29T10:40:39", "published_display": "29 Jun 2026 10:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Satellos Bioscience Inc \u2013 FWB:0IT", "summary": "This article briefly presents the \"Enterprise value to EBIT forward\" metric for Satellos Bioscience Inc, traded on the Frankfurt Stock Exchange under the symbol FWB:0IT. The content indicates that the market for this stock was closed with no trades recorded at the time of the dat", "url": "https://www.tradingview.com/symbols/FWB-0IT/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T17:10:03", "published_display": "28 Jun 2026 17:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Satellos Bioscience Inc \u2013 TSX:MSCL", "summary": "This article provides the \"Price to sales forward\" metric for Satellos Bioscience Inc (TSX:MSCL). It displays a table showing the period, value, change, and change percentage for this financial indicator, noting that the market for MSCL is currently closed with no trades.", "url": "https://www.tradingview.com/symbols/TSX-MSCL/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T09:10:15", "published_display": "28 Jun 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Satellos Bioscience to Present New Data at International Congress Next Month", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/satellos-bioscience-present-data-international-144820182.html", "source_name": "MT Newswires", "published_at": "2026-06-25T14:48:20+00:00", "published_display": "25 Jun 2026 14:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Satellos to Present Clinical Program Updates at ICNMD 2026", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/satellos-present-clinical-program-updates-110000599.html", "source_name": "GlobeNewswire", "published_at": "2026-06-25T11:00:00+00:00", "published_display": "25 Jun 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Satellos (NASDAQ: MSLE) to present new SAT-3247 Duchenne data at ICNMD 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNTkg2WjVwUHZMeTZNYTJQQnk3cTlRalQwWk9XcTRmNTVERXZqdEJWVDh0QWh6M2sxX2g3Y0FHeUQ4UUI5MTdHMDBQR3pSLWJTTmZsUW54NXYtTDAwRk5yVkdpYTBpUFMtMnQyOXR6R200bHdyWmhKdkgtWTdVSXpwdVJYc3RqSHhUQVNBcU1rQUdtZnVIWWNmTkstVmIxdHpmTXVKc1ZheVV0Y0NHUGk0d3ppOTNyMFRKaHh3?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Satellos to show six-month SAT-3247 data in Florence at ICNMD", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxQWVhmQi1naXZocUdGLTRfRHhCTENfN3U5NWJZLXFwTGhnSTFXNmVmWmt5OWc4X0ZVb0Z1MEQwYmJZNG1EVnFPOTRkR1J2emNLYzRNQW5Qcm9zRTJ1S0JJQTVTVFpLcmlxLTBWVmNQV2tWVTNKVDRPbUdwYWFjWkhyZjNJSTJnQzNzZFAteVNaWGF5bjlRVnRzZk5HWUs0WU5iSkIxUFh2VVdjeG5i?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Satellos Bioscience Ord Shs (MSLE) Institutional Confidence", "summary": "", "url": "https://news.google.com/rss/articles/CBMicEFVX3lxTFBfQkpvRmh3WWJaekV0WmJfZTNmaXF4czFrZGV5d1VxMzdBWlk0dk40ejFMc20xcFphaUVMZko5NXlwQWZ1aEFuUDBkSmpYMlNqa3hHY2F0VVhTbjVLS2dnT0w4WjY5R2JjazVrcW5jUDY?oc=5", "source_name": "TradingKey", "published_at": "2026-06-20T18:07:32+00:00", "published_display": "20 Jun 2026 18:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Satellos Bioscience Announces Results of Annual Meeting of Shareholders", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/satellos-bioscience-announces-results-annual-210000032.html", "source_name": "GlobeNewswire", "published_at": "2026-06-17T21:00:00+00:00", "published_display": "17 Jun 2026 21:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Satellos Bioscience (NASDAQ: MSLE) details 2026 director election vote results", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPOUgxYXNId0ZTWUxWYTRBb0dWSG5oY0lmWnVLdnB2a2Q5M2ozUUVKWHY1cGdrRjRzR2JoZmxHQTd4OXo0OUJLQ0tNc3h0TUxUcW1aUl8wWXpiNkNRdkstTkY3OTR0cXl6YWx2bnd6S1pqUHBFVlhJUzl5bTRweFJQWnNNOTVQS3dlMHNzMHFOTi1FajRldG1vb2JFVmZUcXR1Rm5MbC1NTWVfcjM5cVFpSGlwcDljR1pmWTRN?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Satellos shareholders re-elect board, back PwC at annual meeting", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxNa0JpSDNLeC1hRS1KZ1pWYkIxYWtyVjN1dkktNFMtQ25iWF90RjlNRWlCZmMwVEpNX2NXYVM3SmtzWVpmZGhzdGkweWtTVC10UVBEV0xkOXJ2cEgxUlVkS2ZqdDBUenRrVEduTnFlOGNiUDRfdUtiLVV2dDQwYjVrZ2l4b3MyX1I5NFNXeEl0SEQtcTR0MTREZ25tSThRMGNSMGc5YmhNSUlHTzlLZmlwZUZadw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQM0ExNm9zZVBVMzB2cTFsYkhQeDJyeUV5Y1lSdWdsa2V2STFTSFBkYVlrRDJaUmE0bjZVLUxmZEh1UkFPbndtdWVDWmJBcEJaSmpTSlN4RkFkdF9EYkhFUXh3YWxqREkxRllfRXE0bFVuSkMwaExFNmk0UmNoa2R2NmQyb0p1N2pudENMMGMwWmVGT0J5SUxfeE5hT2hpUms1NHR4NzY1VWpNQVFYUWJkUnN3?oc=5", "source_name": "TradingView", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Traders Lose US$134k As Satellos Bioscience Drops", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6AFBVV95cUxPd0ZLeXdIR1Z5ODBHcENJOGlhaXpKYnpGdDV4Si1VNVBZRVhnTEJpWGJOdzdqemM1ZEN2a0hhYmVoSFAzWWpsVTZOZXkxTUdad3pVSDZCZU1VWlkwRlkzbjg2bG1YTF8waUlVTEcxUlkzeWJlOEhxeGtvV2I1N2h0R0h1THNqYlhiNlkwTE9IcC1FZ3REc0ZjUXV1ZWtfRExpWk5vY2ZFRmRsTmJxbk5sYmRIMzFTMUM4WTVOR3BlblVERHROcC1mT3o1UllTQWlmTFJBdkp2RnFUUTY3Zm8wSk4zdUJycGh30gHuAUFVX3lxTE5wdFhLcEcxSktVZkhTWlBRZjhpRllST1lOeW40cFV6TVVFVmpFVTFETE9lYUhLUnpaZHlZMGNKaWZiVXEyQkxCVG95aGthRTZabF9Idl82UHR2cURBWkFPQy1BbWlGWWttYkRvTm1fSWQxTHA0Z2lXTWVpdVh4VUhscGZOWFUtbmQxVVRlVW9FYjg4YXMxaXE5TVBVblFqeVhsQmlsWEc4dlZjWnhDZ1R1UEJQdl9kYmtjY1Nfa3Z4ZjQ5MGw4bjdFdG4yMFE0bVVQaFhIUTA0aVRXNUYtc2xWVXhkMjQxME5JdW9PdkE?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNH stock jumps on Q1 earnings beat and raised guidance to $18.25+", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPTEprdzNMNGZxdkg5Wll5MTlvS1dheXQybm14TERTcGVzcHQzY0llOEpTa0dpZ1hGdHVyNWZ2cFFiWmZRdkl1aUp4YVlTMVJxSDRzaEdzRFB1cW93QzdhSmNxcEZDMWhGX2F0ODJFcjY1Mk1kMVhLNnVJSUhVMHZpRjRtTHo2cXBvbVJ3a05SWlJNMUdrSzFPbA?oc=5", "source_name": "eciks.org", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "PDS BIOTECHNOLOGY ($PDSB) Releases Q1 2026 Earnings | PDSB Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxOcEdqLWM1SmVuNHpvZ2poNU5mOFppaWNtUi1IQVRHTmgxLUpyZHdUSDRnekdzMmVFQzFzUGo2RjlYenpCaTlfcUZhMm1yTzRwWUxnM01WY0libmxIVXNSM3RtMGxMY2RURTdMVW96bGU0SGZXRkE2SnVQdVNNUWw5RWtJQVJMX2pQQnRBRHBKMlRCUDct?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "GE HealthCare (NASDAQ:GEHC) Posts Better-Than-Expected Sales In Q1 CY2026 But Stock Drops", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxOUjRRb0hlcHlOazlmelFaVVJSQWNnRmExZVBEQW1HMmVLTjNyU3d4WElsU05hdGlfYWFSY0twMTNWOVVCY0h4U2dYQ19BQl9pa3o0NWNBLW50WmFsSEVHdmJFV3JabnN5MFZpUWZabjZzY2tjMUtxbndONm9DS3NxTUp3Qjg2dWZnMDR2NXZ2eU80MWhSODVKdVgxZVJ6TWs3RFpCaDFqMXVtVkhmRVlOcWtqYUV1X1FPcGpfdERhRmwzdkZDaWxtSnJnd25Oam4yTnFHTFBkZi0tM1BZdkE?oc=5", "source_name": "StockStory", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Abbott is the most oversold healthcare stock as Q1 earnings roll on (XLV:NYSEARCA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOc2thQjFpazgwaFRfS3NjVXhlTkdFWHNFb240S0Z6akFtQXFIMmFmaXZnQ1A3OFVCQW9DT25OLVBQdGN5Yk52Mk9yUFlSX19ZS3FRTjZoR05zc2FVc25pVHQ0TDVHT2JmVnJabGNCREdLT2stV0IzLVdHWXpFZGU3V1NnVGhYbFRzNURVek41TVRmLWZQZTFYUkc4aXM0a1cwTkNFYTBfVnQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "This \u2018Alpha Male\u2019 Stock Is Profiting as the Strait of Hormuz Remains Closed. Should You Buy It Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxQR2t6RDlBU2JNZ1NYVmUyZGhMWUQxN0Y5VWRJS0NSbDFVc2FoMDkzSEpVMGdpSEs5eXFuT000YmFyYTdzaE95b2o3T2lhWW1WN045cjVSbjdqTm5QdEVRc3NrUFpuSDBNMklYV0xVUExDZnhNWkFOMHo1cjRBQ1ExUWgwRTU5X2JsRjNaZ2lqNENwYzJ5aFR6VHpVekVxMk92UnkwcFM5d08tRjJ4YWkyRVdnbkRyWkNkUEUwQUc1X1oyczZSUlRidXcxb0NFSnFBdUh4Mg?oc=5", "source_name": "Barchart", "published_at": "2026-03-22T07:00:00+00:00", "published_display": "22 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNTTJZRVF4TFNBb3BhMW9VUnBnMVZhenZLNlZJY3Ryc3pGZ3dhZXBDY3pId0I5NFdmVTdiR2EyNXNBZFFuQ1M2M3pUTlRZdXJkbGxaT29mWm4wTG5fU2RtV1hIZWRwZUVNb3BEbTZKX3NPRV9mZVpiY3JBZDdMSDRveW1Jb0lIVmRKLVlidA?oc=5", "source_name": "Market source", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Puma Biotechnology's Stock Plummet Despite Beating Q4 Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQUEQ4TXY0R1lWMTJIcEJySm5iaEl1UkJ6TDMxcUtQYVl3UmxYdlJnaElpdlJDLU0xTTRvT0dsellqX21Tc3lxWW9IbWxHMnFBZGlxajdnUUU2OTNVY0l3NUh0OExMUENwWGxqY1d5dXV3YmRDZm9IRzc1c3FjbUh2cGxvdEJMZ25lYXdjSUliZ0txSjVFOHJhUXNTajBLeVV0M3B4dDk4V3dfQQ?oc=5", "source_name": "Kavout | AI", "published_at": "2026-02-28T09:53:07+00:00", "published_display": "28 Feb 2026 09:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cava Stock Surges 24% After Upbeat Earnings and Strong 2026 Outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQcV9JR0t0QUpQRWhQU0JxOGZld2wxZmNTb0ZoV05TZVBhUjRxRGF2Zno5YWRaVkxKRzNsbk8yY01fdk95S09xcV9aT0FFS1A3Zzhfd0ZLVVVRVU1jY1BiZmZ6T0drMjlfLVNXMTVBZjdtWXdNTEdHTEc2ejFqX1lTREs3eXBhbWRjaUhRWHJMZlYxWGFGZnYwOUJ2Mm9uQQ?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology Stock Skyrockets 65% on Positive Prostate Cancer Treatment Trial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNeEtXZ1k1WGctLWZuX0tYZE5SLWN4MU5KUktLV3NobzVheFpoMkZhdFJrWTdNelAwWGxYZUswazZtMWFUaXEzY3k0QnI0TW9IMGc2UTNzUlNmR1JxZG1JbEpQM0N3N1p4blRjaGdvMExoZzJOYWF3Tk5hajJCTlprZ3dESTVEd0Y4TXhvcElNR3Bqemd3RmNKcGxwa2dSU2phak9paE53c0t3dVFVeGZic2liZ1I0UU80TEM2WUNlOA?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Small-Cap Biotech Stock Is Soaring 29% on Excitement Over Its Prostate Cancer Drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPSG1pQzVIRmhqTkhiWXozT29mTWM0UERfakxmOTZzdm5TZ24wZTVqLUpSWlFyWGVmYnlicGE3ZVYxOVotWU5naGM5aUZVakItUGJLTk1ZVE1mclRHd1N3N0FIWkV2TzFrT2lMNFRjcHhnVVBzTk5vNUFkLTgwNExtRWJYN1hVZzRkVjRlTktkNk1jcnpfQklCamN3NA?oc=5", "source_name": "Barron's", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Satellos price target raised to $40 from $5 at Oppenheimer", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwFBVV95cUxPbk15eDlJdkFmbDlwRGVKRmE5aVBLM0RHdVRfUzFybjBYSXkzdlVITG1zcDFMZGNFeVZfV0lFWVhJeG15aWxYLWxxNUE4UVdJQkFxV3Q2MDF1QnhmUGhOZkNpZUhqZHRDMFN6MVJObFlHaUpQdU9mUnVFbjVpa1VsQnQyVQ?oc=5", "source_name": "Market source", "published_at": "2026-02-11T08:00:00+00:00", "published_display": "11 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 64, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mintz Advises Satellos Bioscience in Its US$57.2 Million Initial US Public Offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQNkhyWjFodUg5MmdPanFXSkIwU0xRVGtIUFB4WkpKUU5tMEpMQ2hHRmNYZkFrVnpOMlBHbW9RQ1N6cUZNQnNNeVVRVnFWeUdwNXI1MUlQamh4ZUZpTHp6c0ZYWFVlY2E3eHAtMkhNTkJNVkx3OTBKMkIzSDBGU18zaXBSSzFJWTVDR041UnFEbjZyYUtNZmk3enZhSzAyNHF2OF9DTVoxd3g5V01kQWFENWs4RGFmX3QwT2c?oc=5", "source_name": "Mintz", "published_at": "2026-02-10T08:00:00+00:00", "published_display": "10 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Price to book forward of Satellos Bioscience Inc \u2013 SWB:0IT", "summary": "This article provides financial information for Satellos Bioscience Inc (SWB:0IT), specifically its price to book forward value. The data is available on TradingView, which aggregates market data from ICE Data Services and reference data from FactSet. The company is listed on the", "url": "https://www.tradingview.com/symbols/SWB-0IT/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-13T05:40:08", "published_display": "13 Jul 2026 05:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech With Muscle Disease Drug Uncovers Results in Trial Data", "summary": "Satellos Bioscience Inc. released promising six-month interim data from its TRAILHEAD study for SAT-3247, an investigational drug for Duchenne muscular dystrophy (DMD). The drug showed reduced muscle fat, increased effort, and stable strength in adult participants, leading analys", "url": "https://www.streetwisereports.com/article/2026/07/09/biotech-with-muscle-disease-drug-uncovers-results-in-trial-data.html", "source_name": "Streetwise Reports", "published_at": "2026-07-11T08:12:14", "published_display": "11 Jul 2026 08:12", "sentiment": "positive", "sentiment_pct": 71, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Satellos Bioscience DMD Drug Shows Early Promise in 6-Month Study Update", "summary": "Satellos Bioscience announced promising interim six-month data for its Duchenne muscular dystrophy (DMD) drug, SAT-3247, from the ongoing TRAILHEAD study involving adult participants. The results indicate encouraging safety and efficacy signals, including improvements in muscle f", "url": "https://www.tradingview.com/news/marketbeat:23ce83e80094b:0-satellos-bioscience-dmd-drug-shows-early-promise-in-6-month-study-update/", "source_name": "TradingView", "published_at": "2026-07-11T07:10:39", "published_display": "11 Jul 2026 07:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Satellos Bioscience Inc. - Common Stock (MSLE) Stock Price, News, Quote & History", "summary": "Satellos Bioscience Inc. (MSLE) stock is trading at $9.79, up 3.71%. Recent news highlights promising early data for its DMD drug SAT-3247 from the TRAILHEAD study and upcoming presentations at medical and investor conferences. The company also recently completed a US$57.2 millio", "url": "https://www.financialcontent.com/quote/NQ:MSLE", "source_name": "FinancialContent", "published_at": "2026-07-11T01:40:32", "published_display": "11 Jul 2026 01:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Satellos Bioscience Delivers Promising DMD Data With Fast Track Win", "summary": "Satellos Bioscience reported promising six-month data from its TRAILHEAD study for SAT-3247 in adult Duchenne muscular dystrophy (DMD) patients, showing muscle fat reduction and improved function. The company also secured FDA Fast Track designation for SAT-3247, which is an oral ", "url": "https://www.streetwisereports.com/article/2026/07/09/satellos-bioscience-delivers-promising-dmd-data-with-fast-track-win.html", "source_name": "Streetwise Reports", "published_at": "2026-07-10T16:40:32", "published_display": "10 Jul 2026 16:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Satellos Bioscience stock price target raised to $18 by H.C. Wainwright on trial data", "summary": "H.C. Wainwright has raised its price target for Satellos Bioscience Inc. (NASDAQ:MSLE) to $18 from $11, while maintaining a Buy rating, following positive interim trial results for its Duchenne muscular dystrophy drug, SAT-3247. The stock saw a 24% increase last week and a 59% ye", "url": "https://www.investing.com/news/analyst-ratings/satellos-bioscience-stock-price-target-raised-to-18-by-hc-wainwright-on-trial-data-93CH-4783828", "source_name": "Investing.com", "published_at": "2026-07-10T07:10:39", "published_display": "10 Jul 2026 07:10", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HC Wainwright Forecasts Strong Price Appreciation for Satellos Bioscience (NASDAQ:MSLE) Stock", "summary": "HC Wainwright has increased its price target for Satellos Bioscience (NASDAQ:MSLE) to $18 from $11, maintaining a \"buy\" rating and suggesting a 100% upside. Despite a recent earnings per share miss, the consensus among analysts is a \"Moderate Buy\" with an average target price of ", "url": "https://www.marketbeat.com/instant-alerts/hc-wainwright-forecasts-strong-price-appreciation-for-satellos-bioscience-nasdaqmsle-stock-2026-07-09/", "source_name": "MarketBeat", "published_at": "2026-07-09T12:40:57", "published_display": "09 Jul 2026 12:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Satellos\u2019 SAT-3247 Shows Muscle Fat Reduction in DMD Adults at Six Months", "summary": "Satellos Bioscience's drug candidate, SAT-3247, has shown promising interim results in its TRAILHEAD study for adult Duchenne muscular dystrophy (DMD) patients. All four participants, aged 21 to 28, experienced a decline in biceps brachii fat fraction, increased upper limb effort", "url": "https://www.clinicaltrialvanguard.com/news/satellos-sat-3247-shows-muscle-fat-reduction-in-dmd-adults-at-six-months/", "source_name": "The Clinical Trial Vanguard", "published_at": "2026-07-09T06:40:57", "published_display": "09 Jul 2026 06:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Satellos Reports Six-Month Interim TRAILHEAD Data Showing Reduced Muscle Fat Fraction, Increased Effort, Stable Strength, Lower CK and Favorable Safety Profile in DMD Adults Treated with SAT-3247", "summary": "Satellos Bioscience announced positive six-month interim data from its TRAILHEAD study for SAT-3247 in adults with Duchenne muscular dystrophy (DMD). The study showed reduced muscle fat fraction, increased upper limb effort, stable strength, lower creatine kinase levels, and a fa", "url": "https://ca.finance.yahoo.com/news/satellos-reports-six-month-interim-103000261.html", "source_name": "Yahoo! Finance Canada", "published_at": "2026-07-09T06:11:34", "published_display": "09 Jul 2026 06:11", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Satellos Bioscience Duchenne Drug Candidate's Interim Data Boosts Confidence", "summary": "Satellos Bioscience released positive six-month interim data from its TRAILHEAD study of SAT-3247 for Duchenne muscular dystrophy (DMD). The drug candidate showed improvements in muscle composition and upper limb activity, maintained stable strength, and continued to demonstrate ", "url": "https://finance.yahoo.com/healthcare/articles/satellos-bioscience-duchenne-drug-candidates-133420130.html", "source_name": "Market source", "published_at": "2026-07-08T20:12:41", "published_display": "08 Jul 2026 20:12", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phase II DMD Trailhead data hike Satellos\u2019 stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxOT2hrZDM5cUtzWUwtWE5aOHA4WVhFdzFsSEZmOWtVeGZIY0FJNjF0ZVFpOHFtT05pMUtrd0x6UlNLeG1yREdrYWNhLVRZYVkyTzQ2UVNHbUp1NUwxQUpMcXdjRG9BOGo2dWFUeGhkLU92Y0tTR0x6SjNFZWk4TGpsU01lUXF1VEhCbFZxVW1wdlhSQQ?oc=5", "source_name": "BioWorld News", "published_at": "2026-07-08T16:00:00+00:00", "published_display": "08 Jul 2026 16:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Satellos Bioscience's Share Rise After SAT-3247 Shows Positive Results for Duchenne MD", "summary": "Satellos Bioscience experienced a surge in its share price following positive preclinical results for its investigational drug, SAT-3247, in treating Duchenne muscular dystrophy (DMD). The study demonstrated that SAT-3247 effectively promoted muscle regeneration and increased mus", "url": "https://www.moomoo.com/news/post/72659943/satellos-bioscience-s-share-rise-after-sat-3247-shows-positive?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-08T15:40:20", "published_display": "08 Jul 2026 15:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Satellos reports positive TRAILHEAD data for DMD drug", "summary": "Satellos Bioscience announced positive six-month interim data from its TRAILHEAD study for Duchenne muscular dystrophy drug SAT-3247. Adult patients showed a mean muscle fat fraction reduction and improvements in upper limb maximum effort and creatine kinase levels. The drug main", "url": "https://grafa.com/en/news/united-states/satellos-bioscience-trailhead-interim-dmd-data", "source_name": "grafa.com", "published_at": "2026-07-08T14:40:20", "published_display": "08 Jul 2026 14:40", "sentiment": "positive", "sentiment_pct": 91, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Satellos Says Interim Phase 2 Data Shows SAT-3247 Improves Muscle Measures in Adult DMD Patients", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/satellos-says-interim-phase-2-122945620.html", "source_name": "MT Newswires", "published_at": "2026-07-08T12:29:45+00:00", "published_display": "08 Jul 2026 12:29", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Satellos\u2019 DMD drug shows better muscle metrics in 4 adults", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxOVFhDaHdPU3ZJUmlPMG1vbWlNZklXQnFnMy02LUwyclFULTdJbFJzcHlHRFdpa29RaldlSjZpd094WXoxaC02ZmJXdVpXS0RYN0Nva2Q1TnUxRFFPMjFoY2FVS1pfX1pxTlIzSU8xeEo2UWczczE5am5Bc0xGeEVCTlFPcE05eDBIc1h4Qml1RlZZaUJLSHZqUERNV19aU0pkd0dsQXlrR0kyZm5wZTRCdGxfNHVaOFk0Q25tbw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-08T10:30:00+00:00", "published_display": "08 Jul 2026 10:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[6-K] Satellos Bioscience Inc. Current Report (Foreign Issuer) | MSLE SEC Filing - Form 6-K", "summary": "Satellos Bioscience Inc. reported positive six-month interim data from its TRAILHEAD Phase 2 study of SAT-3247 in adults with Duchenne muscular dystrophy (DMD), showing reduced muscle fat fraction, increased total effort, stable strength, and a favorable safety profile. The compa", "url": "https://www.stocktitan.net/sec-filings/MSLE/6-k-satellos-bioscience-inc-current-report-foreign-issuer-12f4e1f06014.html", "source_name": "Stock Titan", "published_at": "2026-07-08T10:39:11", "published_display": "08 Jul 2026 10:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "If You Invested $1,000 in Satellos Bioscience Inc (MSCLF)", "summary": "This article analyzes the historical performance of Satellos Bioscience Inc. (MSCLF) stock, detailing how a $1,000 investment would have grown over 1, 5, and 10 years. It also provides an overview of the company, a clinical-stage biotechnology firm focused on restoring muscle rep", "url": "https://www.stocktitan.net/tools/stock-return-calculator/MSCLF", "source_name": "Stock Titan", "published_at": "2026-07-04T07:08:58", "published_display": "04 Jul 2026 07:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drug Developer Scores Major FDA Nod, Eyes Big Gains in Muscle Disease Market", "summary": "Satellos Bioscience Inc. (MSCL:TSX; MSLE:NASDAQ) has received FDA Fast Track designation for its Duchenne muscular dystrophy treatment, SAT-3247, aiming to accelerate its development. This designation, coupled with existing Orphan Drug and Rare Pediatric Disease designations, pos", "url": "https://www.streetwisereports.com/article/2026/07/01/drug-developer-scores-major-fda-nod-eyes-big-gains-in-muscle-disease-market.html", "source_name": "Streetwise Reports", "published_at": "2026-07-03T09:11:47", "published_display": "03 Jul 2026 09:11", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Satellos Bioscience Fast Track Win Fuels DMD Hopes", "summary": "Satellos Bioscience's SAT-3247, a treatment for Duchenne muscular dystrophy (DMD), has received FDA Fast Track designation, aiming to accelerate its regulatory review. The DMD market is projected for significant growth, reaching US$62.13 billion by 2030, presenting a substantial ", "url": "https://www.streetwisereports.com/article/2026/07/02/satellos-bioscience-fast-track-win-fuels-dmd-hopes.html", "source_name": "Streetwise Reports", "published_at": "2026-07-03T00:09:43", "published_display": "03 Jul 2026 00:09", "sentiment": "positive", "sentiment_pct": 82, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Satellos Receives FDA Fast Track Designation for SAT-3247 for the Treatment of Duchenne Muscular Dystrophy", "summary": "Satellos Bioscience Inc. announced that the FDA has granted Fast Track designation to SAT-3247 for Duchenne muscular dystrophy, adding to its Orphan Drug and Rare Pediatric Disease designations. This designation aims to expedite the development and review of SAT-3247, which is cu", "url": "https://www.globenewswire.com/news-release/2026/06/29/3318825/0/en/satellos-receives-fda-fast-track-designation-for-sat-3247-for-the-treatment-of-duchenne-muscular-dystrophy.html", "source_name": "GlobeNewswire", "published_at": "2026-07-02T08:12:14", "published_display": "02 Jul 2026 08:12", "sentiment": "positive", "sentiment_pct": 94, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stocks in play: Satellos Bioscience Inc.", "summary": "Satellos Bioscience Inc. (T.MSCL) received Fast Track designation from the U.S. FDA for SAT-3247, its treatment for Duchenne. Following this announcement, the company's shares were trading up $1.09 at $11.29. This indicates positive market reaction to the regulatory development.", "url": "https://www.theglobeandmail.com/investing/markets/stocks/MSCL-T/pressreleases/3035535/stocks-in-play-satellos-bioscience-inc/", "source_name": "The Globe and Mail", "published_at": "2026-06-30T03:39:58", "published_display": "30 Jun 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Satellos Bioscience up near 10% as SAT-3247 Granted FDA Fast Track Designation", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/satellos-bioscience-near-10-sat-165226766.html", "source_name": "MT Newswires", "published_at": "2026-06-29T16:52:26+00:00", "published_display": "29 Jun 2026 16:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Satellos gets FDA Fast Track for SAT-3247", "summary": "Satellos Bioscience (NASDAQ:MSLE) has received FDA Fast Track designation for its drug SAT-3247, intended for the treatment of Duchenne muscular dystrophy. This designation aims to accelerate the development and regulatory review process for the drug, which already holds Orphan D", "url": "https://grafa.com/en/news/united-states/satellos-msle-sat3247-fda-fast-track-duchenne", "source_name": "grafa.com", "published_at": "2026-06-29T17:40:34", "published_display": "29 Jun 2026 17:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Satellos Bioscience Shares Climb After FDA Fast Track Designation", "summary": "Satellos Bioscience Inc. recently received Fast Track Designation from the FDA for their drug candidate SAT-3257, which aims to treat Duchenne Muscular Dystrophy. This designation is intended to expedite the development and review of drugs for serious conditions with unmet medica", "url": "https://www.moomoo.com/news/post/72197562/satellos-bioscience-shares-climb-after-fda-fast-track-designation?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-06-29T15:09:31", "published_display": "29 Jun 2026 15:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Satellos Bioscience Inc.", "summary": "Satellos Bioscience Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its drug candidate, SAT-3247, for the treatment of Duchenne muscular dystrophy. Following this news, the company's shares (T.MSCL) were trading up $1.09 at $1", "url": "https://www.baystreet.ca/stocksinplayarticles/47448/Stocks-in-Play-Satellos-Bioscience-Inc", "source_name": "Baystreet.ca", "published_at": "2026-06-29T14:40:34", "published_display": "29 Jun 2026 14:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Satellos Bioscience' SAT-3247 Secures US FDA Fast Track Status in Duchenne Muscular Dystrophy", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/satellos-bioscience-apos-sat-3247-120323176.html", "source_name": "MT Newswires", "published_at": "2026-06-29T12:03:23+00:00", "published_display": "29 Jun 2026 12:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA Fast Track boosts Satellos (NASDAQ: MSLE) SAT-3247 Duchenne program", "summary": "Satellos Bioscience Inc. announced its oral small-molecule drug candidate, SAT-3247, has received FDA Fast Track designation for Duchenne muscular dystrophy. This designation, along with existing Orphan Drug and Rare Pediatric Disease designations, is expected to expedite the dev", "url": "https://www.stocktitan.net/sec-filings/MSLE/6-k-satellos-bioscience-inc-current-report-foreign-issuer-f6bda54afa90.html", "source_name": "Stock Titan", "published_at": "2026-06-29T10:40:39", "published_display": "29 Jun 2026 10:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Satellos wins FDA Fast Track for Duchenne drug SAT-3247", "summary": "Satellos Bioscience Inc. announced that the FDA has granted Fast Track designation to its drug candidate SAT-3247 for the treatment of Duchenne muscular dystrophy. This designation, along with existing Orphan Drug and Rare Pediatric Disease designations, aims to expedite the deve", "url": "https://www.stocktitan.net/news/MSLE/satellos-receives-fda-fast-track-designation-for-sat-3247-for-the-bjk0qs9tlpum.html", "source_name": "Stock Titan", "published_at": "2026-06-29T10:40:39", "published_display": "29 Jun 2026 10:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Satellos Bioscience Inc \u2013 FWB:0IT", "summary": "This article briefly presents the \"Enterprise value to EBIT forward\" metric for Satellos Bioscience Inc, traded on the Frankfurt Stock Exchange under the symbol FWB:0IT. The content indicates that the market for this stock was closed with no trades recorded at the time of the dat", "url": "https://www.tradingview.com/symbols/FWB-0IT/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T17:10:03", "published_display": "28 Jun 2026 17:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Satellos Bioscience Inc \u2013 TSX:MSCL", "summary": "This article provides the \"Price to sales forward\" metric for Satellos Bioscience Inc (TSX:MSCL). It displays a table showing the period, value, change, and change percentage for this financial indicator, noting that the market for MSCL is currently closed with no trades.", "url": "https://www.tradingview.com/symbols/TSX-MSCL/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T09:10:15", "published_display": "28 Jun 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Satellos Bioscience to Present New Data at International Congress Next Month", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/satellos-bioscience-present-data-international-144820182.html", "source_name": "MT Newswires", "published_at": "2026-06-25T14:48:20+00:00", "published_display": "25 Jun 2026 14:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Satellos to Present Clinical Program Updates at ICNMD 2026", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/satellos-present-clinical-program-updates-110000599.html", "source_name": "GlobeNewswire", "published_at": "2026-06-25T11:00:00+00:00", "published_display": "25 Jun 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Satellos (NASDAQ: MSLE) to present new SAT-3247 Duchenne data at ICNMD 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNTkg2WjVwUHZMeTZNYTJQQnk3cTlRalQwWk9XcTRmNTVERXZqdEJWVDh0QWh6M2sxX2g3Y0FHeUQ4UUI5MTdHMDBQR3pSLWJTTmZsUW54NXYtTDAwRk5yVkdpYTBpUFMtMnQyOXR6R200bHdyWmhKdkgtWTdVSXpwdVJYc3RqSHhUQVNBcU1rQUdtZnVIWWNmTkstVmIxdHpmTXVKc1ZheVV0Y0NHUGk0d3ppOTNyMFRKaHh3?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Satellos to show six-month SAT-3247 data in Florence at ICNMD", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxQWVhmQi1naXZocUdGLTRfRHhCTENfN3U5NWJZLXFwTGhnSTFXNmVmWmt5OWc4X0ZVb0Z1MEQwYmJZNG1EVnFPOTRkR1J2emNLYzRNQW5Qcm9zRTJ1S0JJQTVTVFpLcmlxLTBWVmNQV2tWVTNKVDRPbUdwYWFjWkhyZjNJSTJnQzNzZFAteVNaWGF5bjlRVnRzZk5HWUs0WU5iSkIxUFh2VVdjeG5i?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Satellos Bioscience Ord Shs (MSLE) Institutional Confidence", "summary": "", "url": "https://news.google.com/rss/articles/CBMicEFVX3lxTFBfQkpvRmh3WWJaekV0WmJfZTNmaXF4czFrZGV5d1VxMzdBWlk0dk40ejFMc20xcFphaUVMZko5NXlwQWZ1aEFuUDBkSmpYMlNqa3hHY2F0VVhTbjVLS2dnT0w4WjY5R2JjazVrcW5jUDY?oc=5", "source_name": "TradingKey", "published_at": "2026-06-20T18:07:32+00:00", "published_display": "20 Jun 2026 18:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Satellos Bioscience Announces Results of Annual Meeting of Shareholders", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/satellos-bioscience-announces-results-annual-210000032.html", "source_name": "GlobeNewswire", "published_at": "2026-06-17T21:00:00+00:00", "published_display": "17 Jun 2026 21:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Satellos Bioscience (NASDAQ: MSLE) details 2026 director election vote results", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPOUgxYXNId0ZTWUxWYTRBb0dWSG5oY0lmWnVLdnB2a2Q5M2ozUUVKWHY1cGdrRjRzR2JoZmxHQTd4OXo0OUJLQ0tNc3h0TUxUcW1aUl8wWXpiNkNRdkstTkY3OTR0cXl6YWx2bnd6S1pqUHBFVlhJUzl5bTRweFJQWnNNOTVQS3dlMHNzMHFOTi1FajRldG1vb2JFVmZUcXR1Rm5MbC1NTWVfcjM5cVFpSGlwcDljR1pmWTRN?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Satellos shareholders re-elect board, back PwC at annual meeting", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxNa0JpSDNLeC1hRS1KZ1pWYkIxYWtyVjN1dkktNFMtQ25iWF90RjlNRWlCZmMwVEpNX2NXYVM3SmtzWVpmZGhzdGkweWtTVC10UVBEV0xkOXJ2cEgxUlVkS2ZqdDBUenRrVEduTnFlOGNiUDRfdUtiLVV2dDQwYjVrZ2l4b3MyX1I5NFNXeEl0SEQtcTR0MTREZ25tSThRMGNSMGc5YmhNSUlHTzlLZmlwZUZadw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQM0ExNm9zZVBVMzB2cTFsYkhQeDJyeUV5Y1lSdWdsa2V2STFTSFBkYVlrRDJaUmE0bjZVLUxmZEh1UkFPbndtdWVDWmJBcEJaSmpTSlN4RkFkdF9EYkhFUXh3YWxqREkxRllfRXE0bFVuSkMwaExFNmk0UmNoa2R2NmQyb0p1N2pudENMMGMwWmVGT0J5SUxfeE5hT2hpUms1NHR4NzY1VWpNQVFYUWJkUnN3?oc=5", "source_name": "TradingView", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Traders Lose US$134k As Satellos Bioscience Drops", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNH stock jumps on Q1 earnings beat and raised guidance to $18.25+", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPTEprdzNMNGZxdkg5Wll5MTlvS1dheXQybm14TERTcGVzcHQzY0llOEpTa0dpZ1hGdHVyNWZ2cFFiWmZRdkl1aUp4YVlTMVJxSDRzaEdzRFB1cW93QzdhSmNxcEZDMWhGX2F0ODJFcjY1Mk1kMVhLNnVJSUhVMHZpRjRtTHo2cXBvbVJ3a05SWlJNMUdrSzFPbA?oc=5", "source_name": "eciks.org", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDS BIOTECHNOLOGY ($PDSB) Releases Q1 2026 Earnings | PDSB Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxOcEdqLWM1SmVuNHpvZ2poNU5mOFppaWNtUi1IQVRHTmgxLUpyZHdUSDRnekdzMmVFQzFzUGo2RjlYenpCaTlfcUZhMm1yTzRwWUxnM01WY0libmxIVXNSM3RtMGxMY2RURTdMVW96bGU0SGZXRkE2SnVQdVNNUWw5RWtJQVJMX2pQQnRBRHBKMlRCUDct?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GE HealthCare (NASDAQ:GEHC) Posts Better-Than-Expected Sales In Q1 CY2026 But Stock Drops", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxOUjRRb0hlcHlOazlmelFaVVJSQWNnRmExZVBEQW1HMmVLTjNyU3d4WElsU05hdGlfYWFSY0twMTNWOVVCY0h4U2dYQ19BQl9pa3o0NWNBLW50WmFsSEVHdmJFV3JabnN5MFZpUWZabjZzY2tjMUtxbndONm9DS3NxTUp3Qjg2dWZnMDR2NXZ2eU80MWhSODVKdVgxZVJ6TWs3RFpCaDFqMXVtVkhmRVlOcWtqYUV1X1FPcGpfdERhRmwzdkZDaWxtSnJnd25Oam4yTnFHTFBkZi0tM1BZdkE?oc=5", "source_name": "StockStory", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abbott is the most oversold healthcare stock as Q1 earnings roll on (XLV:NYSEARCA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOc2thQjFpazgwaFRfS3NjVXhlTkdFWHNFb240S0Z6akFtQXFIMmFmaXZnQ1A3OFVCQW9DT25OLVBQdGN5Yk52Mk9yUFlSX19ZS3FRTjZoR05zc2FVc25pVHQ0TDVHT2JmVnJabGNCREdLT2stV0IzLVdHWXpFZGU3V1NnVGhYbFRzNURVek41TVRmLWZQZTFYUkc4aXM0a1cwTkNFYTBfVnQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This \u2018Alpha Male\u2019 Stock Is Profiting as the Strait of Hormuz Remains Closed. Should You Buy It Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxQR2t6RDlBU2JNZ1NYVmUyZGhMWUQxN0Y5VWRJS0NSbDFVc2FoMDkzSEpVMGdpSEs5eXFuT000YmFyYTdzaE95b2o3T2lhWW1WN045cjVSbjdqTm5QdEVRc3NrUFpuSDBNMklYV0xVUExDZnhNWkFOMHo1cjRBQ1ExUWgwRTU5X2JsRjNaZ2lqNENwYzJ5aFR6VHpVekVxMk92UnkwcFM5d08tRjJ4YWkyRVdnbkRyWkNkUEUwQUc1X1oyczZSUlRidXcxb0NFSnFBdUh4Mg?oc=5", "source_name": "Barchart", "published_at": "2026-03-22T07:00:00+00:00", "published_display": "22 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNTTJZRVF4TFNBb3BhMW9VUnBnMVZhenZLNlZJY3Ryc3pGZ3dhZXBDY3pId0I5NFdmVTdiR2EyNXNBZFFuQ1M2M3pUTlRZdXJkbGxaT29mWm4wTG5fU2RtV1hIZWRwZUVNb3BEbTZKX3NPRV9mZVpiY3JBZDdMSDRveW1Jb0lIVmRKLVlidA?oc=5", "source_name": "Market source", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Puma Biotechnology's Stock Plummet Despite Beating Q4 Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQUEQ4TXY0R1lWMTJIcEJySm5iaEl1UkJ6TDMxcUtQYVl3UmxYdlJnaElpdlJDLU0xTTRvT0dsellqX21Tc3lxWW9IbWxHMnFBZGlxajdnUUU2OTNVY0l3NUh0OExMUENwWGxqY1d5dXV3YmRDZm9IRzc1c3FjbUh2cGxvdEJMZ25lYXdjSUliZ0txSjVFOHJhUXNTajBLeVV0M3B4dDk4V3dfQQ?oc=5", "source_name": "Kavout | AI", "published_at": "2026-02-28T09:53:07+00:00", "published_display": "28 Feb 2026 09:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cava Stock Surges 24% After Upbeat Earnings and Strong 2026 Outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQcV9JR0t0QUpQRWhQU0JxOGZld2wxZmNTb0ZoV05TZVBhUjRxRGF2Zno5YWRaVkxKRzNsbk8yY01fdk95S09xcV9aT0FFS1A3Zzhfd0ZLVVVRVU1jY1BiZmZ6T0drMjlfLVNXMTVBZjdtWXdNTEdHTEc2ejFqX1lTREs3eXBhbWRjaUhRWHJMZlYxWGFGZnYwOUJ2Mm9uQQ?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology Stock Skyrockets 65% on Positive Prostate Cancer Treatment Trial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNeEtXZ1k1WGctLWZuX0tYZE5SLWN4MU5KUktLV3NobzVheFpoMkZhdFJrWTdNelAwWGxYZUswazZtMWFUaXEzY3k0QnI0TW9IMGc2UTNzUlNmR1JxZG1JbEpQM0N3N1p4blRjaGdvMExoZzJOYWF3Tk5hajJCTlprZ3dESTVEd0Y4TXhvcElNR3Bqemd3RmNKcGxwa2dSU2phak9paE53c0t3dVFVeGZic2liZ1I0UU80TEM2WUNlOA?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Small-Cap Biotech Stock Is Soaring 29% on Excitement Over Its Prostate Cancer Drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPSG1pQzVIRmhqTkhiWXozT29mTWM0UERfakxmOTZzdm5TZ24wZTVqLUpSWlFyWGVmYnlicGE3ZVYxOVotWU5naGM5aUZVakItUGJLTk1ZVE1mclRHd1N3N0FIWkV2TzFrT2lMNFRjcHhnVVBzTk5vNUFkLTgwNExtRWJYN1hVZzRkVjRlTktkNk1jcnpfQklCamN3NA?oc=5", "source_name": "Barron's", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Satellos price target raised to $40 from $5 at Oppenheimer", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwFBVV95cUxPbk15eDlJdkFmbDlwRGVKRmE5aVBLM0RHdVRfUzFybjBYSXkzdlVITG1zcDFMZGNFeVZfV0lFWVhJeG15aWxYLWxxNUE4UVdJQkFxV3Q2MDF1QnhmUGhOZkNpZUhqZHRDMFN6MVJObFlHaUpQdU9mUnVFbjVpa1VsQnQyVQ?oc=5", "source_name": "Market source", "published_at": "2026-02-11T08:00:00+00:00", "published_display": "11 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 64, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mintz Advises Satellos Bioscience in Its US$57.2 Million Initial US Public Offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQNkhyWjFodUg5MmdPanFXSkIwU0xRVGtIUFB4WkpKUU5tMEpMQ2hHRmNYZkFrVnpOMlBHbW9RQ1N6cUZNQnNNeVVRVnFWeUdwNXI1MUlQamh4ZUZpTHp6c0ZYWFVlY2E3eHAtMkhNTkJNVkx3OTBKMkIzSDBGU18zaXBSSzFJWTVDR041UnFEbjZyYUtNZmk3enZhSzAyNHF2OF9DTVoxd3g5V01kQWFENWs4RGFmX3QwT2c?oc=5", "source_name": "Mintz", "published_at": "2026-02-10T08:00:00+00:00", "published_display": "10 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 93, "total_relevant": 69, "sentiment_summary": {"positive": 25, "negative": 2, "neutral": 42, "score": 60, "total": 69, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 81, "events": [{"event": "general", "label": "Market update", "weight": 22.9, "count": 41}, {"event": "earnings", "label": "Earnings", "weight": 9.64, "count": 18}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 2.75, "count": 5}, {"event": "analyst", "label": "Analyst action", "weight": 1.65, "count": 3}, {"event": "guidance", "label": "Guidance", "weight": 1.45, "count": 2}], "positive_events": 25, "negative_events": 2}, "market_context": {"has_market_context": true, "latest_close": 9.79, "latest_week": "2026-07-10", "one_week_move": 31.9, "four_week_move": 70.3, "twelve_week_move": 12.5, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.0, "market_dynamics_buy_signal": false, "relative_strength": null, "fair_value_gap": 21.2, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "negative", "expectation_probability": 40.4669, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+31.9% over one week, +70.3% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 70, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 9}, {"label": "Market source", "count": 8}, {"label": "TradingView", "count": 6}, {"label": "Streetwise Reports", "count": 4}, {"label": "MT Newswires", "count": 4}, {"label": "GlobeNewswire", "count": 3}, {"label": "simplywall.st", "count": 3}, {"label": "Moomoo", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 62}, {"label": "Industry context", "count": 7}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 41}, {"label": "Earnings", "count": 18}, {"label": "Regulatory and legal", "count": 5}, {"label": "Analyst action", "count": 3}, {"label": "Guidance", "count": 2}]}, "insights": [{"label": "Weighted tone", "value": "60/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "81/100 classification confidence."}, {"label": "Company focus", "value": "62", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "4", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+31.9% over one week, +70.3% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Price to book forward of Satellos Bioscience Inc \u2013 SWB:0IT"}], "updated_at": "2026-07-16T12:57:16.640554+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}